Vorinostat and Palliative Radiotherapy

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase I study. Side-effects when combined with standard palliative radiotherapy.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oslo University Hospital
• Treatments: Histone Deacetylase Inhibitors; Vorinostat

Criteria

Inclusion Criteria:

• Pelvic malignancy

• Palliative radiation treatment planed

• ECOG <3

• Age>18 years

Exclusion Criteria:

• Previous pelvic radiotherapy

• Uncontrolled diarrhea

• Insulin-dependent diabetes mellitus

• BMI<18.5